A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease
A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease
Start Date21 Feb 2022
Sponsor / Collaborator-
100 Clinical Results associated with α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor
Login to view more data
100 Translational Medicine associated with α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor
Login to view more data
0 Patents (Medical) associated with α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.